Information on EC 3.2.1.35 - hyaluronoglucosaminidase

New: Word Map on EC 3.2.1.35
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY
3.2.1.35
-
RECOMMENDED NAME
GeneOntology No.
hyaluronoglucosaminidase
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
-
-
-
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
also hydrolyses 1,4-beta-D-glycosidic linkages between N-acetyl-galactosamine or N-acetylgalactosamine sulfate and glucuronic acid in chondroitin, chondroitin 4- and 6-sulfates, and dermatan
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
also hydrolyses 1,4-beta-D-glycosidic linkages between N-acetyl-galactosamine or N-acetylgalactosamine sulfate and glucuronic acid in chondroitin, chondroitin 4- and 6-sulfates, and dermatan
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
also hydrolyses 1,4-beta-D-glycosidic linkages between N-acetyl-galactosamine or N-acetylgalactosamine sulfate and glucuronic acid in chondroitin, chondroitin 4- and 6-sulfates, and dermatan
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
also hydrolyses 1,4-beta-D-glycosidic linkages between N-acetyl-galactosamine or N-acetylgalactosamine sulfate and glucuronic acid in chondroitin, chondroitin 4- and 6-sulfates, and dermatan
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
also hydrolyses 1,4-beta-D-glycosidic linkages between N-acetyl-galactosamine or N-acetylgalactosamine sulfate and glucuronic acid in chondroitin, chondroitin 4- and 6-sulfates, and dermatan
Q8UVT7
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
endoglycosidase with exoglycosidase activity
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
enzyme is a beta-1,4-glucosidase, substrate binding groove, enzyme-substrate complex structure, catalytic groups and reaction mechanism
Q08169
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
hydrolase mechanism
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
specifically hydrolyses 1,4-beta-D-glycosidic linkages, reaction mechanism, simulation of product formation process, active site
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
reaction mechanism and three-dimensional structure
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
reaction mechanism and three-dimensional structure, catalytic residue is Glu113, substrate positioning residues, overview
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
reaction mechanism and three-dimensional structure, catalytic residue is Glu149, substrate positioning residues, overview
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
reaction mechanism and three-dimensional structure, catalytic residues of isozymes Hyal1-Hyal4 are Glu131, Glu135, Glu129, and Glu147, respectively, substrate positioning residues, active site structure of isozymes, overview
-
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
the enzyme contains four hyaluronan binding sites [B(X)7B]
Q801Z8
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
condensation
-
-
hydrolysis of O-glycosyl bond
-
-
-
-
hydrolysis of O-glycosyl bond
Q8UVT7
-
transglycosylation
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Glycosaminoglycan degradation
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
hyaluronate 4-glycanohydrolase
Also hydrolyses 1,4-beta-D-glycosidic linkages between N-acetyl-galactosamine or N-acetylgalactosamine sulfate and glucuronic acid in chondroitin, chondroitin 4- and 6-sulfates, and dermatan.
SYNONYMS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
BmHYA1
P86100
-
BPH-20
-
-
chondritinase I
-
-
-
-
chondroitin sulfate hydrolase
-
-
chondroitinase
-
-
-
-
chondroitinase
Q8UVT7
-
chondroitinase I
Q8UVT7
-
Cumulase
-
human recombinant hyaluronidase
Dietrich's hyaluronidase
R4J7Z9
-
endo-alpha-N-acetyl-hexosaminidase
-
-
endo-beta-N-acetyl-D-hexosaminidases hydrolase
-
-
endo-beta-N-acetylhexosaminidase
-
-
HAase
Q08169
-
HAase
-
-
HAase
Q6RHW2, Q6RHW3, Q6RHW4
-
HPH-20
-
-
human PH-20
-
-
Hyal
Q08169
-
Hyal
-
-
Hyal
-
-
Hyal
Q6RHW2, Q6RHW3, Q6RHW4
-
Hyal 1
Q12794
-
Hyal 1
Q76HN1
isoform
HYAL 2
Q9Z2Q3
isoform
HYAL 3
Q76HM9
isoform
HYAL 4
-
isoform
Hyal-1
P85841
isoform
Hyal-2
Q12891
-
Hyal-2
W0HFN9
isoform
Hyal-3
O43820
-
Hyal-4
Q2M3T9
-
HYAL1
Q12794
isoform
HYAL1
Q76HN1
-
HYAL1-v1
Q12794
alternatively spliced and enzymatically inactive variant of HYAL1
HYAL1-v3
-
isoform
Hyal2
-
-
Hyal2
Q12891
gene name
Hyal2
Q12891
isoform
Hyal2
O35632
-
Hyal2
Q9Z2Q3
-
HYAL3
O43820
-
HYAL3
-
-
HYAL3
Q8VEI3
-
HYAL3-v1
-
isoform
HYAL3-v2
-
isoform
HYAL5
-
-
hyaluronate 4-glycanohydrolase
-
-
hyaluronidase
-
-
-
-
hyaluronidase
-
-
hyaluronidase
Q08169
-
hyaluronidase
-
-
hyaluronidase
Q7YS45
-
hyaluronidase
-
-
hyaluronidase
-
-
hyaluronidase
Caenorhabditis elegans N2
-
-
-
hyaluronidase
-
-
hyaluronidase
-
-
hyaluronidase
B3EWP2
-
hyaluronidase
-
-
hyaluronidase
-
-
hyaluronidase
Eusimulium latipes
-
-
hyaluronidase
-
-
hyaluronidase
-
-
hyaluronidase
-
isoenzyme Hyal1
hyaluronidase
O43820
-
hyaluronidase
O60502
-
hyaluronidase
Q12794
-
hyaluronidase
Q12891
-
hyaluronidase
-
-
hyaluronidase
R4J7Z9
-
hyaluronidase
-
-
hyaluronidase
P86100
-
hyaluronidase
Q8VEI3
-
hyaluronidase
-
-
hyaluronidase
-
-
hyaluronidase
Odagmia ornata
-
-
hyaluronidase
-
-
hyaluronidase
-
-
hyaluronidase
Palamneus gravimanus
-
-
hyaluronidase
-
-
hyaluronidase
-
-
hyaluronidase
-
-
hyaluronidase
Q76HM9, Q76HN1, Q9Z2Q3
-
hyaluronidase
-
-
hyaluronidase
-
-
hyaluronidase
Q6RHW2, Q6RHW3, Q6RHW4
-
hyaluronidase
Q801Z8
-
hyaluronidase
synthetic construct
EU152302
-
hyaluronidase
P85841, W0HFN9
-
hyaluronidase
Vipera elegans
-
-
hyaluronidase
Q8UVT7
-
hyaluronidase 1
-
-
hyaluronidase 2
-
-
hyaluronidase 2
Q12891
-
hyaluronidase 2
-
-
hyaluronidase 2
O35632
-
hyaluronidase 3
O43820
-
hyaluronidase-1
-
-
hyaluronidase-1
Q12794
-
hyaluronidase-1
Q12794
isoform
hyaluronidase-1
Q76HN1
-
hyaluronidase-1
Q8UVT7
-
hyaluronidase-2
Q12891
-
hyaluronidase-2
Q12891
isoform
hyaluronidase-2
Q9Z2Q3
-
hyaluronidase-4
-
-
hyaluronidase-5
-
-
hyaluronoglucosaminidase
-
-
hyaluronoglucosaminidase 1
Q12794
-
Hyaluronoglucosaminidase 1-type hyaluronidase
Q12794
-
hyaluronoglucosaminidase 2
Q12891
-
hyaluronoglucosidase
-
-
-
-
hyaluronoglucosidase
Q8UVT7
-
HYase
-
-
HYase
-
-
HYase
-
-
hylB
-
gene name
jaagsiekte sheep retrovirus receptor
-
-
LUCA-1
Q12794
gene name
LUCA-2
Q12891
gene name
Luca-3
O43820
gene name
LUCA2
Q12891
gene name
MGEA5
O60502
-
Mu toxin
-
-
-
-
Neopermease
-
commercial preparation
OTH
-
-
PH-20
Q7YS45
-
PH-20
-
-
PH-20
-
-
rHuPH20
-
-
SFHYA1
Q801Z8
-
SPAM1
-
-
SPAM1
-
-
Sperm surface protein PH-20
-
-
-
-
spreading factor
-
-
spreading factor
-
-
testicular HAse
-
-
testicular hyaluronidase
-
-
vitrase
-
commercial preparation
XKH1
Q8UVT7
-
CAS REGISTRY NUMBER
COMMENTARY
37326-33-3
-
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
expression in Pichia pastoris GS115, expression vector pPIC9, together with human serum albumin, expression in Escherichia coli BL21 DE3, vector pMW172, fusion protein; hyaluronoglucosaminidase precursor
UniProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
commercial preparation, Sigma H 3884
-
-
Manually annotated by BRENDA team
type 1-S
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
buffalo
-
-
Manually annotated by BRENDA team
WormBase accession T22C8.2, cDNA: WBGene 00011923 (WormBase); strain N2
-
-
Manually annotated by BRENDA team
Caenorhabditis elegans N2
WormBase accession T22C8.2, cDNA: WBGene 00011923 (WormBase); strain N2
-
-
Manually annotated by BRENDA team
goat
-
-
Manually annotated by BRENDA team
guinea pig
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
Eusimulium latipes
-
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
funnel web spider
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
; expression in human bronchial epithelial cell (HBE)
SwissProt
Manually annotated by BRENDA team
gene mgea5, bifunctional enzyme possessing hyaluronidase and beta-N-acetylglucoaminidase activities
SwissProt
Manually annotated by BRENDA team
HYAL1 gene of the the LUCA region
SwissProt
Manually annotated by BRENDA team
HYAL2 gene of the the LUCA region
SwissProt
Manually annotated by BRENDA team
hyaluronidase-1 precursor
SwissProt
Manually annotated by BRENDA team
isozyme splice variant HYAL1v1; isozyme splice variant HYAL1v2; isozyme splice variant HYAL1v3; isozyme splice variant HYAL1v4; isozyme splice variant HYAL1v5
SwissProt
Manually annotated by BRENDA team
isozyme splice variant HYAL3v1; isozyme splice variant HYAL3v2; isozyme splice variant HYAL3v3; wild-type isozyme HYAL3wt
SwissProt
Manually annotated by BRENDA team
isozymes Hyal1-Hyal4, and HPH-20, or SPAM1
-
-
Manually annotated by BRENDA team
wild-type isozyme HYAL1
-
-
Manually annotated by BRENDA team
Brown spider
-
-
Manually annotated by BRENDA team
6 isozymes in sperm
-
-
Manually annotated by BRENDA team
nude mice, 2 enzyme forms with one or five isoforms, respectively
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
2 isoforms, intraspecific variability in isoforms with different geographical distribution in the indian subcontinent
-
-
Manually annotated by BRENDA team
isozyme NNH1
-
-
Manually annotated by BRENDA team
isozyme NNH2
-
-
Manually annotated by BRENDA team
two isozymes NNH1 and NNH2
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
Norway lobster
-
-
Manually annotated by BRENDA team
Odagmia ornata
-
-
-
Manually annotated by BRENDA team
Ovis aries aries
ovine
-
-
Manually annotated by BRENDA team
Palamneus gravimanus
Indian black scorpion
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
Hyal1; gene HYAL1
SwissProt
Manually annotated by BRENDA team
Hyal2; gene HYAL2
SwissProt
Manually annotated by BRENDA team
Hyal3; gene HYAL3
SwissProt
Manually annotated by BRENDA team
stonefish
SwissProt
Manually annotated by BRENDA team
synthetic construct
using the information of preferred Pichia pastoris codons as provided by Genscript, Inc., the native sequence is de novo synthesized to create a fully codon-optimized cDNA (Hya delta c) and the synthetic gene is expressed in Pichia
EU152302
Genbank
Manually annotated by BRENDA team
Vipera elegans
2 isoforms
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
-
HYAL5-deficient epididymal sperm is functionally normal, the loss of SPAM1 results in a remarkably increased accumulation of sperm on the surface or outer edge of the cumulus
malfunction
-
enzyme deficiency reduces survival in macrophages compared to the wild type and stimulates a significantly higher release of proinflammatory cytokines, such as interleukin (IL)-1beta, IL-6, and tumor necrosis factor alpha than the wild type in macrophages as well as in mice
malfunction
-
enzyme deficiency reduces survival in macrophages compared to the wild type and stimulates a significantly higher release of proinflammatory cytokines, such as interleukin (IL)-1beta, IL-6, and tumor necrosis factor alpha than the wild type in macrophages as well as in mice
-
physiological function
-
Hyal2, through direct interactions with CD44 and possibly some pericellular hyaluronidase activity requiring acidic foci, suppresses the formation or the stability of the glycocalyx, modulates ezrin-radixin-moesin-related cytoskeletal interactions, and diminishes cell motility
physiological function
-
SPAM1 is involved in sperm penetration through the cumulus matrix
physiological function
-
although fully fertile, Hyal3 null sperm shows delayed cumulus penetration and reduced acrosomal exocytosis. Spam1 null mutants lacking sperm adhesion molecule 1 have significantly diminished Hyal3 activity
physiological function
-
generation of a deletion mutant in the Caenorhabditis elegans orthologue of mammalian hyaluronidase, Hya-1. Mutant animals are viable and grossly normal, but exhibit defects in vulval morphogenesis and egg-laying and show increased staining with alcian blue, consistent with an accumulation of glycosaminoglycan. A hya-1::GFP reporter is expressed in a restricted pattern in somatic tissues of the animal with strongest expression in the intestine, the PLM sensory neurons and the vulva. Total protein extracts from wild-type animals exhibit chondroitin-degrading but not hyaluronan-degrading activity. Chondroitinase activities are observed at both neutral and acidic pH conditions while both neutral and acidic activities are absent in extracts from Hya-1 mutant strains
physiological function
E5RWZ0
the Synanceia verrucosa hyaluronidase enhances the capillary permeability-increasing activity of the Synanceia verrucosa toxin, neoverrucotoxin
physiological function
-
hyaluronidase has a strong influence on the intracellular survival of Streptococcus agalactiae and proinflammatory cytokine expression, suggesting that it plays a key role in pathogenicity
physiological function
-
the enzyme play a special role in the testes of adult mice being involved in the maturation of sperm or during fertilization
physiological function
-
hyaluronidase has a strong influence on the intracellular survival of Streptococcus agalactiae and proinflammatory cytokine expression, suggesting that it plays a key role in pathogenicity
-
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
4-S-chondroitin sulfate + H2O
?
show the reaction diagram
Q08169
-
-
-
?
4-S-chondroitin sulfate + H2O
?
show the reaction diagram
synthetic construct
EU152302
-
-
-
?
4-S-chondroitin sulfate + H2O
?
show the reaction diagram
O43820, Q2M3T9
-
-
-
?
6-S-chondroitin sulfate + H2O
?
show the reaction diagram
O43820, Q2M3T9
-
-
-
?
6-S-chondroitin sulfate + H2O
?
show the reaction diagram
Q08169
the enzyme is capable of degrading chondroitin sulfate C at a rate of around 40% compared to its hyaluronidase activity
-
-
?
6-S-chondroitin sulfate + H2O
?
show the reaction diagram
synthetic construct
EU152302
the enzyme is capable of degrading CS-C at a rate of around 40% compared to its hyaluronidase activity
-
-
?
chitin + H2O
?
show the reaction diagram
-
-
-
-
?
chitin + H2O
?
show the reaction diagram
-
12 h incubation
-
-
?
chondroitin + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin + H2O
GlcAbeta(1-3)GalNAcbeta(1-4)GlcAbeta(1-3)GalNAc + ?
show the reaction diagram
Caenorhabditis elegans, Caenorhabditis elegans N2
-
-
main product
-
ir
chondroitin 4-sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin 4-sulfate + H2O
?
show the reaction diagram
B3EWP2
-
-
-
?
chondroitin 4-sulfate + H2O
?
show the reaction diagram
-
28% activity compared to sodium hyaluronate
-
-
?
chondroitin 6-sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin 6-sulfate + H2O
?
show the reaction diagram
B3EWP2
-
-
-
?
chondroitin 6-sulfate + H2O
?
show the reaction diagram
-
19% activity compared to sodium hyaluronate
-
-
?
chondroitin B sulfate + H2O
?
show the reaction diagram
Q08169
very little hydrolase activity towards chondroitin sulfate B (dermatan sulfate)
-
-
?
chondroitin sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate + H2O
?
show the reaction diagram
R4J7Z9
-
-
-
?
chondroitin sulfate + H2O
?
show the reaction diagram
Caenorhabditis elegans N2
-
-
-
-
?
chondroitin sulfate A + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate A + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate A + H2O
oligosaccharides + ?
show the reaction diagram
-
acting at the same rate as with hyaluronic acid
-
-
?
chondroitin sulfate A + H2O
oligosaccharides + ?
show the reaction diagram
-
production of even-numbered oligosaccharides only produced by lysosomal hyaluronidase
-
?
chondroitin sulfate A + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate A + H2O
?
show the reaction diagram
Q08169
-
-
-
?
chondroitin sulfate A + H2O
?
show the reaction diagram
-
poor substrate
-
-
?
chondroitin sulfate B + H2O
?
show the reaction diagram
Q08169
very little hydrolase activity
-
-
?
chondroitin sulfate B + H2O
?
show the reaction diagram
synthetic construct
EU152302
very little hydrolase activity
-
-
?
chondroitin sulfate C + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate C + H2O
?
show the reaction diagram
Q08169
-
-
-
?
chondroitin sulfate C + H2O
?
show the reaction diagram
-
acting at the same rate as with hyaluronic acid
-
?
chondroitin sulfate D + H2O
?
show the reaction diagram
-
-
-
-
?
Collagen + H2O
?
show the reaction diagram
-
-
-
?
dematan + H2O
?
show the reaction diagram
B3EWP2
-
-
-
?
dermatan + H2O
?
show the reaction diagram
-
7% activity compared to sodium hyaluronate
-
-
?
hyaluronan + H2O
tetraoligosaccharides + hexaoligosaccharides
show the reaction diagram
-
-
-
r
hyaluronan + H2O
tetraoligosaccharides + hexaoligosaccharides
show the reaction diagram
-
-
after complete digestion
?
hyaluronan + H2O
?
show the reaction diagram
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
O43820, Q12794
-
-
?
hyaluronan + H2O
?
show the reaction diagram
O43820, Q12794, Q12891
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
Phlebotomus papatasi, Eusimulium latipes, Chrysops viduatus, Odagmia ornata
-
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
P86100
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
E5RWZ0
-
-
-
?
hyaluronan + H2O
?
show the reaction diagram
E7FI87
-
catalyzes the endolytic hydrolysis of beta-1,4 glycosidic linkages in hyaluronan. Products are saturated hyaluronan-disaccharides
-
?
hyaluronan + H2O
?
show the reaction diagram
Q8UVT7
complete degradation, absolutely specific for
-
?
hyaluronan + H2O
?
show the reaction diagram
O43820, Q12794
complete degradation, absolutely specific for
-
?
hyaluronan + H2O
?
show the reaction diagram
O43820, Q12794
wild-type isozyme HYAL1 sequence, amino acid residues 301-330, is critical for hyaluronidase activity
-
?
hyaluronan + H2O
?
show the reaction diagram
-
a fluorescent substrate (FRET-HA) to quantitatively assess hyaluronidase activity is developed. Hyaluronan (HA)is dual labeled with fluorescein amine and rhodamine B amine. The fluorescein amine fluorescence signal is significantly quenched and the rhodamine B amine signal is significantly enhanced due to fluorescence resonance energy transfer (FRET). In the presence of bovine testes hyaluronidase, cleavage of HA disrupts FRET, resulting in a loss of the fluorescein amine quenching that is dependent on both enzyme concentration and time. Increase in the fluorescein amine signal can be conveniently monitored in both noncontinuous and continuous fashions
-
-
?
hyaluronan + H2O
?
show the reaction diagram
-
HPLC and MS analyses of the products reveal the existance of oligosaccharides which are not produced under hydrolysis conditions, but during transglycosylation by the enzyme, suggesting that a novel enzyme is present as a contaminant in commercial BTH, which acts as an N-deacetylase of N-acetylglucosamine at the reducing terminal of hyaluronan oligosaccharides
-
-
?
hyaluronan + H2O
?
show the reaction diagram
-
hyaluronan deposition and turnover is even more abundant and more rapid in malignant tissues. The proportion of low molecular weight (LMW) fragments of HA is greater in tumors and tumor patients than in the normal
-
-
?
hyaluronan + H2O
?
show the reaction diagram
-
hyaluronan fragments are used with a molar mass ranging from 800 g/mol to 250000 g/mol and native hyaluronan to study the influence of the chain length of hyaluronan on the kinetics of its HAase-catalyzed hydrolysis. The initial hydrolysis rate strongly varies with hyaluronan chain length. The ability of HA chains to form an efficient enzyme-substrate complex is maximum for hyaluronan molar masses ranging from 3000 to 20000 g/mol. Shorter hyaluronan chains are too short to form a stable complex and longer hyaluronan chains encounter difficulties in forming a complex, due to steric hindrance. As the chain length decreases the HAase increasingly catalyses transglycosylation rather than hydrolysis. Two hyaluronan chain populations, corresponding to hyaluronan chain molar masses lower and higher than approximately 20000 g/mol are identified and related to the bi-exponential character
-
-
?
hyaluronan + H2O
N-acetylglucosamine + D-glucuronate
show the reaction diagram
-
complete degradation, absolutely specific for
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q12794
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q76HM9
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q8VEI3
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q08169
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q12891
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q9Z2Q3
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q76HN1
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
O35632
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
from Streptococcus zooepidemicus
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
from Streptococcus zooepidemicus, degradation
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
from Streptococcus zooepidemicus, degradation
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
from Streptococcus zooepidemicus, degradation
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
absolute specificity for hyaluronan
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
B3EWP2
highly specific substrate with 10fold higher activity compared to chondroitin 4-sulfate, chondroitin 6-sulfate, or dermatan
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
hexasaccharides + tetrasaccharides
show the reaction diagram
-
absolutely specific for
main products, with N-acetyl-beta-D-glucosamine at the reducing end, cleavage of beta-1,4-glycosidic linkage, not beta-1,3-glycosidic linkage
?
hyaluronan + H2O
oligosaccharides
show the reaction diagram
-
specific cleavage of beta-1,4-glucosidic linkages
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
Q08169
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
Q801Z8
human substrate
-
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
-
human skin sections
-
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
-
the enzyme is required for fertility facilitating the penetration of sperm through the cumulus mass in the ovum
-
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
-
isozyme NNH2 shows endoglycosidase activity, absolute specific for in vitro, substrate from human skin
-
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
-
the enzyme shows low activity, degradation
-
-
?
hyaluronan + H2O
tetrasaccharides units of hyaluronan
show the reaction diagram
-
absolutely specific for, absolutely specific for, cleavage of beta-1,4-glycosidic linkages, of human skin, extracellular matrix
-
-
?
hyaluronan decasaccharide + H2O
hyaluronan tetrasaccharide + hyaluronan hexasaccharide + hyaluronan octasaccharide +
show the reaction diagram
-
-
31.5% hyaluronan tetrasaccharide, 48.3% hyaluronan hexasaccharide, 14.7% hyaluronan octasaccharide, 5.5% hyaluronan decasaccharide
-
?
hyaluronan octasaccharide + H2O
hyaluronan tetrasaccharide + hyaluronan hexasaccharide
show the reaction diagram
-
-
46.8% hyaluronan tetrasaccharide, 32.7% hyaluronan hexasaccharide, 20.5% hyaluronan octasaccharide. Enzyme generates a disaccharide intermediate from hyaluronan oligosaccharide, the majority of which is transferred to the nonreducing ends of other oligosaccharides, only traces being released as free disaccharide. When hyaluronan octasaccharide, with an unsaturated glucuronic acid at the nonreducing end, is used as a substrate, only a tetrasaccharide product is detected by HPLC. MS shows that the product is a mixture of equal amounts of two tetrasaccharides, one with and the other without the unsaturated glucuronic acid. This suggests that, in the case of substrates with a double bond at the nonreducing end, a tetrasaccharide is cleaved off instead of a disaccharide
-
?
hyaluronan oligosaccharides + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
specific cleavage of beta-1,4-glucosidic linkages
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q08169
-
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
from umbilical cord
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
O60502
from umbilical cord
-
?
hyaluronate + H2O
oligosaccharides
show the reaction diagram
-
from human umbilical cord
establishing of a rapid, sensitive PAGE method for analysis of hyaluronan oligosaccharides
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
O43820, Q2M3T9
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
Q12794
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
Q8VEI3
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
P85841, W0HFN9
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
R4J7Z9
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
spreading factor for dermonecrosis
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
spreading factor for dermonecrosis
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
spreading factor for dermonecrosis
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
involved in inflammatory reactions, exists as inactive form activated by metal ions
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
important in hyaluronate catabolism in the vitreous
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
endo-mucopolysaccharidase hydrolysing acid mucopolysaccharides from connective tissue and chondroitin-sulfate in cartilage
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
two isoforms necessary for penetration of extracellular vestments surrounding eggs prior fertilization
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
from rooster comb
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
Caenorhabditis elegans N2
-
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
-
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
tetraoligosaccharides + ?
show the reaction diagram
-
complete hydrolysis
-
?
hyaluronic acid + H2O
tetraoligosaccharides + ?
show the reaction diagram
-
complete hydrolysis
-
?
hyaluronic acid + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
?
hyaluronic acid hexasaccharide + H2O
?
show the reaction diagram
-
not only lower oligosaccharides, but also higher oligosaccharides are produced, transglycosylation activity, multiple disaccharide units are rapidly transferred from one substrate molecule to another
-
-
r
hyaluronic acid hexasaccharide + H2O
octasaccharide + disaccharide + tetrasaccharide
show the reaction diagram
-
hydrolysis in disaccharide units, transglycosylation activity, smallest substrate
-
r
hyaluronic acid octasaccharosyl-pyridylaminoside + H2O
hexasaccharosyl-pyridylaminoside + ?
show the reaction diagram
-
smallest substrate, hydrolysis of even-numbered oligosaccharides with glucuronic acid at the non-reducing terminal by successive removal of disaccharide units from the non-reducing terminal
-
?
sodium hyaluronate + H2O
?
show the reaction diagram
-
100% activity
-
-
?
hyaluronic acid-rich cumulus matrix + H2O
?
show the reaction diagram
-
investment of oocyte during sperm invasion
-
?
additional information
?
-
-
hyaluronan is degraded by L-ascorbic acid, D-isoascorbic acid, and dehydroascorbic acid themselves, only slightly by L-gulonic-gamma-lactone, D-saccharic-1,4-lactone, and alpha-D-glucoheptonic-gamma-lactone
-
?
additional information
?
-
-
no activity with chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, chondroitin sulfates D and E, and heparin, no activity with 4-nitrophenyl-beta-glucuronide or 4-nitrophenyl-N-acetyl-beta-glucoaminide
-
?
additional information
?
-
-
simulation of progress of product distribution from short oligosaccharides with the Monte Carlo method using the probalistic model
-
?
additional information
?
-
O43820, Q12794
the splice variant is enzymatically inactive
-
?
additional information
?
-
O43820, Q12794
alternative splicing controls the cellular expression of enzymatically active hyaluronidase
-
?
additional information
?
-
O43820, Q12794
alternative splicing controls the cellular expressionof enzymatically active hyaluronidase
-
?
additional information
?
-
-
CD44-mediated specific role of certain populations of testicular enzyme in the induction of angiogenesis
-
?
additional information
?
-
-
enzyme activity in serum from tumour-bearing mice, e.g. H460M or SA87 cell grafted mice, is increased, the level is corrsponding to the tumour mass, not in serum from CB193 cell grafted mice
-
?
additional information
?
-
O43820, Q12794
increased concentration of HYAL1-type enzyme correlates with tumour progression and is a marker for grade (G) 2 or 3 bladder cancer
-
?
additional information
?
-
Q08169
the enzyme is a major allergen of bee venom which can induce serious, occasionally fatal, systemic IgE-mediated anaphylactic reactions in humans
-
?
additional information
?
-
-
HPH-20 or SPAM1, sperm adhesion molecule 1, is a bifunctional enzyme, which is also an adhesion molecule with binding properties to the cumulus mass surrounding the ovum
-
-
-
additional information
?
-
-
isozyme NNH2 is nontoxic, but indirectly potentiates the hemorrhagic activity of hemorrhagic complex-I
-
-
-
additional information
?
-
-
the enzyme indirectly potentiates the myotoxicity of VRV-PL-VIII, a phospholipolytic myotoxin, and also the hemorrhagic potency of a hemorrhagic complex-I
-
-
-
additional information
?
-
-
no activity with chondroitin sulfates, heparin, and different chitosans
-
-
-
additional information
?
-
-
no activity with chondroitin sulfates, heparin, chitosan, 4-nitrophenyl-N-acetyl-beta-D-glucosaminide, or 4-nitrophenyl-beta-D-glucuronide
-
-
-
additional information
?
-
-
the jaagsiekte sheep retrovirus receptor Hyal2 interacts specifically with the virus particles of the amphotropic murine leukemia virus-pseudotype vectors/JSRV-pseudotype vector envelope protein, binding kinetics, the binding inhibits virus entry into cells, overview
-
-
-
additional information
?
-
-
chondroitin, chondroitin sulfate A, chondroitin sulfate B, chondroitin sulfate C, chondroitin sulfate D, heparin, and chitosan are no substrates
-
-
-
additional information
?
-
-
does not hydrolyze chondroitin sulfate B, heparin, or heparan sulfate
-
-
-
additional information
?
-
O43820, Q12794, Q12891
Hyal 1 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
-
additional information
?
-
O43820, Q12794, Q12891
Hyal 2 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
-
additional information
?
-
O43820, Q12794, Q12891
Hyal 3 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
-
additional information
?
-
Q12794, Q12891
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 or hyaluronidase-2 suppresses tumour growth in vivo but not in vitro, HYAL2 inhibits experimental lung metastases in nu/nu mice
-
-
-
additional information
?
-
Q12794, Q12891
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 suppresses tumour growth in vivo but not in vitro
-
-
-
additional information
?
-
O43820, Q2M3T9
among hyaluronidases Hyal-1 to Hyal-4, only rHuHyal-4 exhibits chondroitinase activity with both 6-S-chondroitin sulfate and 4-S-chondroitin sulfate as standard substrates
-
-
-
additional information
?
-
-
enzyme additionally catalyzes transglycosylation reactions of chondroitin sulfates. Barium salt of chondroitin sulfates enhances transglycosylation, the zinc salt of chondroitin sulfates inhibits transglycosylation
-
-
-
additional information
?
-
-
minimum substrate for bovine testicular hyaluronidase is the hyaluronan hexasaccharide
-
-
-
additional information
?
-
E7FI87
no substrate: chondroitin
-
-
-
additional information
?
-
R4J7Z9
no activity with dermatan sulfate and heparan sulfate
-
-
-
additional information
?
-
-
the enzyme depolymerizes various chondroitin sulfate isoforms to a similar extent, suggesting broad substrate specificity
-
-
-
additional information
?
-
-
the enzyme strongly prefers D-glucuronic acid-(2-O-sulfate)-GalNAc(6-O-sulfate)-containing sequences typical in chondroitin sulfate D
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
hyaluronan + H2O
?
show the reaction diagram
O43820, Q12794
complete degradation, absolutely specific for
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q12891
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
O35632
-
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
B3EWP2
highly specific substrate with 10fold higher activity compared to chondroitin 4-sulfate, chondroitin 6-sulfate, or dermatan
-
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
-
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
Q08169
-
-
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
-
human skin sections
-
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
-
the enzyme is required for fertility facilitating the penetration of sperm through the cumulus mass in the ovum
-
-
?
hyaluronan + H2O
tetrasaccharides units of hyaluronan
show the reaction diagram
-
absolutely specific for
-
-
?
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q08169
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
-
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
spreading factor for dermonecrosis
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
spreading factor for dermonecrosis
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
spreading factor for dermonecrosis
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
involved in inflammatory reactions, exists as inactive form activated by metal ions
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
important in hyaluronate catabolism in the vitreous
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
endo-mucopolysaccharidase hydrolysing acid mucopolysaccharides from connective tissue and chondroitin-sulfate in cartilage
-
-
-
hyaluronic acid + H2O
?
show the reaction diagram
-
two isoforms necessary for penetration of extracellular vestments surrounding eggs prior fertilization
-
-
-
hyaluronic acid-rich cumulus matrix + H2O
?
show the reaction diagram
-
investment of oocyte during sperm invasion
-
?
additional information
?
-
O43820, Q12794
alternative splicing controls the cellular expression of enzymatically active hyaluronidase
-
?
additional information
?
-
O43820, Q12794
alternative splicing controls the cellular expressionof enzymatically active hyaluronidase
-
?
additional information
?
-
-
CD44-mediated specific role of certain populations of testicular enzyme in the induction of angiogenesis
-
?
additional information
?
-
-
enzyme activity in serum from tumour-bearing mice, e.g. H460M or SA87 cell grafted mice, is increased, the level is corrsponding to the tumour mass, not in serum from CB193 cell grafted mice
-
?
additional information
?
-
O43820, Q12794
increased concentration of HYAL1-type enzyme correlates with tumour progression and is a marker for grade (G) 2 or 3 bladder cancer
-
?
additional information
?
-
Q08169
the enzyme is a major allergen of bee venom which can induce serious, occasionally fatal, systemic IgE-mediated anaphylactic reactions in humans
-
?
additional information
?
-
-
HPH-20 or SPAM1, sperm adhesion molecule 1, is a bifunctional enzyme, which is also an adhesion molecule with binding properties to the cumulus mass surrounding the ovum
-
-
-
additional information
?
-
-
isozyme NNH2 is nontoxic, but indirectly potentiates the hemorrhagic activity of hemorrhagic complex-I
-
-
-
additional information
?
-
-
the enzyme indirectly potentiates the myotoxicity of VRV-PL-VIII, a phospholipolytic myotoxin, and also the hemorrhagic potency of a hemorrhagic complex-I
-
-
-
additional information
?
-
O43820, Q12794, Q12891
Hyal 1 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
-
additional information
?
-
O43820, Q12794, Q12891
Hyal 2 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
-
additional information
?
-
O43820, Q12794, Q12891
Hyal 3 is expressed in airway epithelium and may operate in a coordinated fashion to depolymerize hyaluronan during inflammation associated with up-regulation of TNF-alpha and IL-1beta, such as allergen-induced asmatic responses
-
-
-
additional information
?
-
Q12794, Q12891
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 or hyaluronidase-2 suppresses tumour growth in vivo but not in vitro, HYAL2 inhibits experimental lung metastases in nu/nu mice
-
-
-
additional information
?
-
Q12794, Q12891
this gene may play an important role in the development of lung and renal malignancies, the expression of hyaluronidase-1 suppresses tumour growth in vivo but not in vitro
-
-
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Ca2+
-
1.8fold increasing activity at 5 mM
CaCl2
-
more effective activation than with NaCl
Co2+
-
18% enhanced activity at 0.8 mM
diphosphate
-
30% activation
Mg2+
-
1.8fold increasing activity at 5 mM
MgCl2
-
more effective activation than with NaCl
NaCl
B3EWP2
maximum activity in the presence of 0.2 M NaCl
NaCl
-
maximum activity in the presence of 0.15 M NaCl
NO3-
-
18% enhanced activity at 0.8 mM
additional information
-
not activated by Cl-
additional information
-
not affected by Cu2+, Zn2+, and Co2+
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-3-[[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
-
-
(2R,3S)-3-[[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
-
-
(2S)-2-(3,4-dimethoxy-5-oxo-2,5-dihydrofuran-2-yl)-2-hydroxyethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
(2S)-2-[3,4-bis(benzyloxy)-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-21-cyclohexyl-28-hydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-23,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[(2-methylbutanoyl)oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic aci
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosidur
-
-
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic a
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2E)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
-
-
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-16,22-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-21-cyclohexyl-16,22-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,23,28-trihydroxyolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,28-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(5R)-3,4-bis(benzyloxy)-5-(1,2-dihydroxyethyl)furan-2(5H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
(5R)-5-(1,2-dihydroxyethyl)-3,4-dimethoxyfuran-2(5H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
(7S)-7-(1,2-dihydroxyethyl)-2,3-dihydrofuro[3,4-b][1,4]dioxin-5(7H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
2-hydroxy-2-[(5R)-7-oxo-2,3,5,7-tetrahydrofuro[3,4-b][1,4]dioxin-5-yl]ethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
2-mercaptoethanol
-
-
2-mercaptoethanol
Palamneus gravimanus
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl ([1-[2-(benzyloxy)ethenylidene]but-2-yn-1-yl]oxy)ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-phenoxyundecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-[[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]undecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 2,2-dimethylpropaneperoxoate
-
inactive at concentrations less than 1.1 mM, at pH 5.0
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 3-(2-phenylethenylidene)hex-4-yneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 6-(benzyloxy)hexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 6-phenoxyhexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl benzenecarboperoxoate
-
33% inhibition at 1.43 mM
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl decaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl dodecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octadecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tetradecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tridecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl undecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [(1-prop-1-yn-1-ylpenta-1,2-dien-1-yl)oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[2-(2-phenylethenylidene)pent-3-yn-1-yl]oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl {[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy}ethaneperoxoate
-
-
3-(4-methylpiperazin-1-yl)-5-phenyl-1H-indole
-
0.05 mM, 23% inhibition in stains-all assay, pH 7.0
3-amino-6-chloro-N-(diaminomethylidene)-5-[ethyl(propan-2-yl)amino]pyrazine-2-carboxamide
-
-
6-palmitoyl-L-ascorbic acid
-
0.005 mM, 95% inhibition at pH 7.0
6-palmitoyl-L-ascorbic acid
-
0.005 mM, 93% inhibition at pH 7.0
acetylated hyaluronic acid
-
-
-
Ag+
-
82% inhibition at 0.8 mM
ajmaline
-
-
apigenin
-
strong inhibition
apigenin
-
52% inhibition at 1 mM and 10 mM
aristolochic acid
-
complete inhibition
aristolochic acid
P85841, W0HFN9
;
ascorbic acid palmitate
-
inhibition at pH 7: 99%, at pH 3.5: 99%
beta1,4-galacto-oligosaccharides
-
partially sulfated and non-sulfated forms, especially tri-, tetra-, and pentasaccharides
-
beta1,4-galacto-oligosaccharides
-
partially sulfated and non-sulfated forms, especially tri-, tetra-, and pentasaccharides, IC50 values
-
butylated hydroxytoluene
-
-
Ca2+
-
inhibition at 300 mM
Ca2+
B3EWP2
complete inhibition at 0.2 mM
Ca2+
-
65% residual activity at 50 mM
chlorogenic acid
-
-
chondroitin O-sulfate
-
IC50 = 0.00133 mg/ml
chondroitin O-sulfate
-
complete inhibition from 0.012-1.2 mg/ml
chondroitin O-sulfate
-
inhibition between 50-500 ng/ml
Chondroitin sulfates
-
-
cimicifugic acid H
-
-
cimicifugic acid I
-
-
cimicifugic acid J
-
-
citrate
-
-
clinopodic acid C
-
-
clinopodic acid E
-
-
Cu2+
-
complete inhibition at 0.8 mM
Cu2+
-
67% inhibition at 5 mM
Cu2+
-
inhibition reversed by cysteine
curcumin
-
IC50 is 0.057 mM
curcumin
-
-
cysteine
-
complete inhibition from 0.012-1.2 mg/ml
D-isoascorbic acid
-
-
decyl gallate
-
-
dehydroascorbic acid
-
weak inhibition
dermatan O-sulfate
-
IC50 = 0.00133 mg/ml
-
dermatan O-sulfate
-
10% inhibition at 50 ng/ml
-
dermatan sulfate
-
-
dermatan sulfate
-
-
dexamethasone
-
-
Dextran
-
-
Dextran sulfate
-
-
-
dimethyl sulfoxide
-
-
disodium cromoglycate
-
-
DTT
-
-
DTT
Palamneus gravimanus
-
-
EDTA
Palamneus gravimanus
-
-
EDTA
-
complete inhibition at 10 mM
Fe2+
-
complete inhibition at 0.8 mM
Fe2+
-
-
Fe2+
-
77% residual activity at 50 mM
Fe3+
-
complete inhibition at 0.8 mM
Fe3+
-
inhibition reversed by diphosphate
Fe3+
-
20% residual activity at 50 mM
flavone
-
-
fukinolic acid
-
-
fully O-sulfonated chondroitin sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00135 mg/ml
-
fully O-sulfonated dermatan sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00133 mg/ml
-
fully O-sulfonated heparan sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00128 mg/ml
-
fully O-sulfonated heparin
-
50% inhibition at 0.00114 mg/ml
-
fully O-sulfonated hyaluronan
-
50% inhibition at 0.00078 mg/ml
glutathione
Palamneus gravimanus
-
-
glutathione
-
non-competitive
glutathione
-
non-competitive, complete inhibition at 1.8 mg/ml
glycyrrhizic acid
-
-
heparan O-sulfate
-
IC50 = 0.00128 mg/ml
-
Heparan sulfate
-
43% inhibition at 500 ng/ml
Heparan sulfate
-
-
heparin
-
IC50 = 0.00114 mg/ml, non-competitive inhibition; noncompetitive
heparin
-
58.4% inhibition at 1.2 mg/ml
heparin
-
73% inhibition at 500 ng/ml
heparin
-
65% inhibition at 5 mM
heparin
-
inhibition can be prevented by addition of NaCl
heparin
-
16-18 kDa
heparin
-
inhibitory potency can be regulated by chemical modification, in form of conformational changes, with aldehyde dextran, increase in modification degree decreases the inhibition, best at 70-90% modification, overview
heparin
-
-
heparin
Palamneus gravimanus
-
-
heparin
P86100
-
heparin
-
90% inhibition at 1.5 mg/ml
heparin O-sulfate
-
IC50 = 0.00114 mg/ml, competitive and non-competitive inhibitory effects
-
heptyl gallate
-
-
hexyl gallate
-
-
Hg2+
-
complete inhibition at 0.8 mM
Hg2+
-
moderate inhibition at 20 mM
Hg2+
-
43% inhibition at 5 mM
hyaluronan O-sulfate
-
IC50 = 0.00078 mg/ml
hyaluronic acid
-
inhibitory at high concentrations (0.73 g/l)
indomethacin
-
IC50 is 0.086 mM
indomethacin
-
-
isorhamnetin
-
51.04% inhibition at 0.2 mM
kaempferol
-
36% inhibition at 1 mM
kaempferol
-
50.75% inhibition at 0.2 mM
L-Arginine-HCl
-
8% residual activity at 1 mM
L-ascorbic acid
-
-
L-ascorbic acid
-
inactive at concentrations less than 100 mM, at pH 5.0
L-ascorbic acid decanoate
-
-
L-ascorbic acid dodecanoate
-
-
L-ascorbic acid tridecanoate
-
-
L-ascorbic acid undecanoate
-
-
L-cysteine
Palamneus gravimanus
-
-
lepidepyrone
-
-
lycopic acid A
-
-
lycopic acid B
-
-
Mg2+
-
inhibition at 300 mM
Mg2+
B3EWP2
complete inhibition at 0.2 mM
Mg2+
-
46% residual activity at 50 mM
N-(4,6-dimethylpyridin-2-yl)-(1-ethylindole-3-yl)acetamide
-
inhibition at pH 7: 3%, but at pH 3.5: 134% activation
N-(4,6-dimethylpyridin-2-yl)-[5-bromo-1-(4-methyl)indole-3-yl]carboxamide
-
inhibition at pH 7: 37%, but at pH 3.5: 117% activation
N-(4-chlorobenzyl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide
-
0.05 mM, 66% inhibition at pH 7.0
N-(4-chlorobenzyl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide
-
0.05 mM, 21% inhibition at pH 7.0
N-(4-fluorobenzyl)-1-benzyl-1H-indole-2-carboxamide
-
0.05 mM, 80% inhibition at pH 7.0
N-(4-fluorobenzyl)-1-benzyl-1H-indole-2-carboxamide
-
0.05 mM, 61% inhibition at pH 7.0
N-(pyridin-4yl)-[5-bromo-1-(4-fluorobenzyl)indole-3-yl]carboxamide
-
inhibition at pH 7: 50%, but at pH 3.5: 120% activation
N-acetyl-L-cysteine
-
non-competitive
N-acetyl-L-cysteine
-
non-competitive, complete inhibition at 1.8 mg/ml
n-propyl gallate
-
-
NaCl
-
complete but reversible loss of activity above 0.2 M
NaCl
-
sharp decrease of activity above 0.15 M
NaCl
-
complete inhibition at 1 mM
NaCl
B3EWP2
1 M NaCl significantly reduces the enzyme activity
NaCl
-
0.5 M causes 92% inhibition
nitrated hyaluronic acid
-
-
-
nonyl gallate
-
-
nordihydroguaiaretic acid
-
-
octyl 3,4-dihydroxybenzoate
-
-
octyl 3,5-dihydroxybenzoate
-
-
octyl gallate
-
-
partially sulfated neomycin
-
the non-sulfated neomycin is not inhibitory
-
partially sulfated planteose
-
the non-sulfated planteose is not inhibitory, IC50 is 0.008 mM
partially sulfated planteose
-
the non-sulfated planteose is not inhibitory, IC50 is 0.005 mM
partially sulfated verbascose
-
2 forms, the non-sulfated verbascose is not inhibitory, IC50 are 0.040 mM and 0.003 mM
-
partially sulfated verbascose
-
2 forms, the non-sulfated verbascose is not inhibitory
-
polymer from gentisic acid
-
-
-
quercetin
-
complete inhibition
quercetin
-
54.63% inhibition at 0.2 mM
quinol
-
irreversible inhibition
quinone
-
irreversible inhibition
reserpine
-
-
rosmarinic acid
-
-
rutin
-
-
rutin
-
61.87% inhibition at 0.2 mM
schizotenuin A
-
-
serum protein
-
from human, 33.7% inhibition at 1.2 mg/ml
-
serum protein
-
inhibition strongly influenced by salts, that in- or decrease the effect
-
shomaside A
-
-
shomaside B
-
-
shomaside C
-
-
shomaside D
-
-
shomaside E
-
-
sorghum bran
-
the ability of ethanolic extracts of bran from six cultivated varieties of Sorghum bicolor to inhibit hyaluronidase activity in vitro is assessed. Each extract inhibits hyaluronidase activity with this order of potency: Sumac higher than Shanqui Red higher than Black higher than Mycogen higher than Fontanelle higher than White sorghum. Hyaluronidase inhibition correlate positively with total phenolic content and ferric reducing antioxidant power values for each bran extract. Inhibition is not only due to condensed tannins (proanthocyanidins) because the Black sorghum cultivar lacks condensed tannins but has abundant anthocyanins and other polyphenols
-
sulfated 2-hydroxyphenyl monolactobioside
-
IC50 is 0.025 mM
-
sulfated hydroquinone galactoside
-
IC50 is 0.006 mM
sulfated hydroquinone galactoside
-
IC50 is 0.015 mM
Tannic acid
-
IC50 is 0.070 mM
Tannic acid
-
-
Urea
Palamneus gravimanus
-
-
Urea
-
complete inhibition at 10 mM
Zn2+
-
-
Zn2+
-
inhibition at 300 mM
additional information
-
enzyme stably covalently linked to activated glycosaminoglycans, such as heparin, dextran and dermatan sulfate, is reduced in its activity and the inhibitory effect of free heparin is increased, while chondroitin sulfate stabilizes the enzyme against heparin inhibition, effect of glycosaminoglycan fragments with different residues, at different pH values, overview
-
additional information
-
iridoids from leaves and stem of malaysian medical plants Rothmannia macrophylla and Saprosma scortechinii are poor inhibitors, e.g. sapromoside A, D, E, G, asperulosidic acid, paederosidic acid, 6-epi-paederosidic acid, methylpaederosidate, 6alpha-hydroxygeniposide, asperuloside, paederoside, macrophylloside, and gardenogenin A and B, overview
-
additional information
-
blocking of CD44-receptors inhibits the enzyme-induced tubular structure formation of endothelial cells
-
additional information
-
no inhibition by saccharic acid, poor inhibitors are alpha-D-glucoheptonic-gamma-lactone, D-saccharic-1,4-lactone, L-gulonic-gamma-lactone, D-ribonic-gamma-lactone, and D-gluconic-gamma-lactone
-
additional information
-
ascorbic acid is a poor inhibitor, the plant-derived inhibitors inhibit isozyme NNH1, reduce the local tissue damage, and retard the easy diffusion of systemic toxins and increase survival time, inhibitory potencies, overview
-
additional information
-
inhibition curves, overview
-
additional information
-
not inhibited by gallic acid, methyl gallate, ethyl gallate, propyl gallate, butyl galate, dodecyl gallate, octyl 3-hydroxybenzoate, and octyl 4-hydroxybenzoate
-
additional information
-
at pH 4 bovine serum albumin (BSA) is able to compete with HAase to form electrostatic complexes with hyaluronan, liberating HAase which recovers its catalytic activity, the BSA concentration necessary to prevent the HAase binding is 25times higher at pH 5.25 than at pH 4.0
-
additional information
-
the residual activities normalized to 100% at 0 concentrations of Terminalia chebula extract are reduced to 84% at 0.1 mg/ml, 68% at 0.5 mg/ml, 57% at 1 mg/ml, 26% at 1.5 mg/ml, 20% at 3 mg/ml, and 7% at 30 mg/ml
-
additional information
-
the residual activities normalized to 100% at 0 concentrations of Terminalia chebula extract are reduced to 88% at 0.1 mg/ml, 78% at 0.5 mg/ml, 58 at 1 mg/ml, 49% at 1.5 mg/ml, 29% at 3 mg/ml, and 15% at 30 mg/ml
-
additional information
-
inhibition data for human and bovine enzyme differ, bovine enzyme is not applicable as an alternative to human PH-20
-
additional information
-
aminomethyl indole derivatives with phenyl substitution at position 5 have higher activity. More lipophilic compounds have better inhibition against the hyaluronidase enzyme
-
additional information
-
not affected by ascorbic acid, phenylmethylsulfonyl fluoride, dithiothreitol, glutathione (reduced), or L-cysteine
-
additional information
-
the ethanol extract of of the stem bark of Butea monosperma dose-dependently inhibits enzyme with IC50 of 0.1254 mg/ml
-
additional information
-
the ethanol extract of of the stem bark of Butea monosperma dose-dependently inhibits enzyme with IC50 of 0.0494 mg/ml
-
additional information
-
the ethanol extract of of the stem bark of Butea monosperma dose-dependently inhibits enzyme with IC50 of 0.012 mg/ml
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Bovine serum albumin
-
enhanced activity of 22% at 0.26 mg/ml
-
Bovine serum albumin
-
activation up to 0.2 g/l
-
Bovine serum albumin
-
-
-
Bovine serum albumin
-
at pH 3.0 to 5.3, at low bovine serum albumin concentrations, HAase activity increases as bovine serum albumin concentration increases, and at high bovine serum albumin concentrations, HAase activity decreases as bovine serum albumin concentration increases
-
bovine serum albumine
-
-
-
compound 48/80
-
-
cysteine
-
60% activation
EDTA
-
up to 24% enhanced activity
interleukin 1-beta
O43820, Q12794, Q12891
acts synergistically with TNF-alpha to increase gene expression and activity; acts synergistically with TNF-alpha to increase gene expression and activity; acts synergistically with TNF-alpha to increase gene expression and activity
-
N-(4,6-dimethylpyridin-2-yl)-(1-ethylindole-3-yl)acetamide
-
acts as an inhibitor at pH 7 and at pH 3.5 activity is increased to 134%
N-(4,6-dimethylpyridin-2-yl)-[5-bromo-1-(4-methyl)indole-3-yl]carboxamide
-
acts as an inhibitor at pH 7 and at pH 3.5 activity is increased to 117%
N-(pyridin-4yl)-[5-bromo-1-(4-fluorobenzyl)indole-3-yl]carboxamide
-
acts as an inhibitor at pH 7 and at pH 3.5 activity is increased to 120%
NaCl
-
0.12 M required for optimum activity
NaCl
-
optimum activity between 0.05-0.1 M
NaCl
-
prevents inhibition by impurities present in the substrate
NaCl
-
-
NaCl
Palamneus gravimanus
-
activates at 0.15 M
NaCl
-
optimal activity in the presence of 300 mM NaCl
NaCl
E7FI87
0.1-0.4 M NaCl increases the enzyme's activity by 20-30%
NaCl
E5RWZ0
maximum activity at 0.15 M
TNF-alpha
O43820, Q12794, Q12891
acts synergistically with interleukin 1-beta to increase gene expression and activity; acts synergistically with interleukin 1-beta to increase gene expression and activity; acts synergistically with interleukin 1-beta to increase gene expression and activity
-
Lysozyme
-
lysozyme can enhance HAase activity over a wide pH range from 3 to 9. Lysozyme can compete with HAase to form complexes with yaluronan, HAase is catalytically active over this whole pH domain when LYS limits its complexation with HA, and either the pI of bovine testicular HAase is high or positive patches on the surface of HAase allow the formation of electrostatic HA-HAase complexes at high pH values
-
additional information
Q8UVT7
activity is optimal at physiological salt concentrations
-
additional information
E7FI87
addition of MgCl2, CaCl2, and EDTA shows no significant effect
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.12
Chondroitin
-
apparent KM, substrate calculated as disaccharide
0.48
chondroitin sulfate
-
apparent KM, substrate calculated as disaccharide
0.66
chondroitin sulfate A
-
at pH 4.5 and 37C
2.16
chondroitin sulfate C
-
at pH 4.5 and 37C
0.5
chondroitin sulfate D
-
at pH 4.5 and 37C
-
0.038
hyaluronan
-
Hyal1 wild-type
0.0381
hyaluronan
-
wild-type, Vmax: 12.5 micromol/min/mg
0.048
hyaluronan
Palamneus gravimanus
-
pH 5.0, 37C
0.103
hyaluronan
-
Hyal1 mutant N216A; mutant N216A, Vmax: 10 micromol/min/mg
0.11
hyaluronan
-
Hyal1 mutant S245A; mutant S245A, Vmax: 10.7 micromol/min/mg
0.181
hyaluronan
-
Hyal1 mutant D129N; mutant D129N, Vmax: 1.9 micromol/min/mg
0.367
hyaluronan
-
Hyal1 mutant Y202F; mutant Y202F, Vmax: 6.7 micromol/min/mg
0.00091
hyaluronic acid
-
in 5 mM ammonium acetate, at 37C and pH 5.0
49.3
hyaluronic acid from Streptococcus pyogenes (35 kDa)
-
apparent KM, substrate calculated as disaccharide
-
additional information
hyaluronoic acid
-
0.48 mg/ml; value in mg/ml
-
additional information
hyaluronoic acid
-
0.71 mg/ml; value in mg/ml
-
additional information
additional information
-
kinetics
-
additional information
additional information
-
Km strongly decreases with increasing HA chain sizes
-
additional information
additional information
-
Km (hyaluronan) (microgram/ml): 4.91, Vmax (hyaluronan): 2.02 U/min
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.082
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.112
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.251
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.092
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.12
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.153
(2R,3S)-3-[[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.138
(2R,3S)-3-[[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.0285
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-21-cyclohexyl-28-hydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0264
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-23,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0193
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0364
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0556
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.052
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0302
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0242
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[(2-methylbutanoyl)oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic aci
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.02
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosidur
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0552
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0515
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0449
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic a
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0405
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2E)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0368
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0297
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0387
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0549
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-16,22-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0487
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-21-cyclohexyl-16,22-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0241
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0249
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0266
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,23,28-trihydroxyolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0288
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,28-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.21
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl ([1-[2-(benzyloxy)ethenylidene]but-2-yn-1-yl]oxy)ethaneperoxoate
-
at pH 5.0
0.105
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-phenoxyundecaneperoxoate
-
at pH 5.0
0.037
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-[[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]undecaneperoxoate
-
at pH 5.0
2.006
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 3-(2-phenylethenylidene)hex-4-yneperoxoate
-
at pH 5.0
1.38
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl decaneperoxoate
-
at pH 5.0
0.208
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl dodecaneperoxoate
-
at pH 5.0
0.057
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
-
at pH 5.0
0.039
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octadecaneperoxoate
-
at pH 5.0
0.071
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tetradecaneperoxoate
-
at pH 5.0
0.096
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tridecaneperoxoate
-
at pH 5.0
0.58
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl undecaneperoxoate
-
at pH 5.0
0.188
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]ethaneperoxoate
-
at pH 5.0
0.543
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[2-(2-phenylethenylidene)pent-3-yn-1-yl]oxy]ethaneperoxoate
-
at pH 5.0
0.008
ascorbic acid palmitate
-
pH: 7.0
0.018
ascorbic acid palmitate
-
pH: 3.5
0.525
cimicifugic acid H
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.143
cimicifugic acid I
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.193
cimicifugic acid J
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.0801
clinopodic acid C
-
in 0.1 M acetate buffer, at 37C
0.0828
clinopodic acid E
-
in 0.1 M acetate buffer, at 37C
0.057
curcumin
-
IC50 is 0.057 mM
0.58
decyl gallate
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.45
disodium cromoglycate
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.144
fukinolic acid
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.026
glycyrrhizic acid
-
at pH 3.5
0.112
heptyl gallate
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.253
hexyl gallate
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.086
indomethacin
-
IC50 is 0.086 mM
0.378
L-ascorbic acid decanoate
-
at pH 3.5
0.076
L-ascorbic acid dodecanoate
-
at pH 3.5
0.05
L-ascorbic acid tridecanoate
-
at pH 3.5
0.143
L-ascorbic acid undecanoate
-
at pH 3.5
3.3
lepidepyrone
-
at 37C
0.134
lycopic acid A
-
in 0.1 M acetate buffer, at 37C
0.141
lycopic acid B
-
in 0.1 M acetate buffer, at 37C
0.078
N-(4,6-dimethylpyridin-2-yl)-[5-bromo-1-(4-methyl)indole-3-yl]carboxamide
-
pH: 7.0
0.046
N-(pyridin-4yl)-[5-bromo-1-(4-fluorobenzyl)indole-3-yl]carboxamide
-
pH: 7.0
4
N-acetyl-L-cysteine
-
in 0.2 M sodium acetate buffer pH 5.5 containing 0.15 M NaCl at 37C
0.167
nonyl gallate
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.902
octyl 3,4-dihydroxybenzoate
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.113
octyl 3,5-dihydroxybenzoate
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.106
octyl gallate
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.005
partially sulfated planteose
-
the non-sulfated planteose is not inhibitory, IC50 is 0.005 mM
0.008
partially sulfated planteose
-
the non-sulfated planteose is not inhibitory, IC50 is 0.008 mM
0.04
partially sulfated verbascose
-
2 forms, the non-sulfated verbascose is not inhibitory, IC50 are 0.040 mM and 0.003 mM
-
0.2401
rosmarinic acid
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.309
rosmarinic acid
-
in 0.1 M acetate buffer, at 37C
0.545
rosmarinic acid
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.241
schizotenuin A
-
in 0.1 M acetate buffer, at 37C
0.573
shomaside A
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.43
shomaside B
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.663
shomaside C
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.658
shomaside D
-
IC50 above 0.658 mM, in 0.1 mM acetate buffer (pH 3.5), at 37C
0.79
shomaside E
-
IC50 above 0.79 mM, in 0.1 mM acetate buffer (pH 3.5), at 37C
0.025
sulfated 2-hydroxyphenyl monolactobioside
-
IC50 is 0.025 mM
-
0.006
sulfated hydroquinone galactoside
-
IC50 is 0.006 mM
0.015
sulfated hydroquinone galactoside
-
IC50 is 0.015 mM
0.07
Tannic acid
-
IC50 is 0.070 mM
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
0.0000245
Q08169
recombinant enzyme from crude extract, in 100 mM sodium phosphate, pH 5.0, at 37C
0.000239
Q08169
recombiannt enzyme after 9.6fold purification, in 100 mM sodium phosphate, pH 5.0, at 37C
0.00184
-
venom gland extract, at 37C
0.03767
-
after 20.4fold purification, at 37C
0.08
O43820, Q2M3T9
pH 3.5, 37C
0.49
Q08169
culture supernatant
0.49
synthetic construct
EU152302
culture supernatant
0.85
-
crude enzyme, at pH 3.8 and 27C
1.5
O43820, Q2M3T9
pH 7.1, 37C
1.55
O43820, Q2M3T9
pH 7.1, 37C
2.4
O43820, Q2M3T9
pH 3.5, 37C
4.77
Q08169
ion exchange
4.77
synthetic construct
EU152302
ion exchange
7.47
Ovis aries aries
-
-
20.4
-
after 24fold purification, at pH 3.8 and 27C
22.6
O43820, Q2M3T9
pH 3.5, 37C
61.15
O43820, Q2M3T9
pH 3.5, 37C
6412
Palamneus gravimanus
-
turbidity reduction units/min/mg, purified enzyme
additional information
-
activity measured as turbidicity reducing units; development of a flow injection assay method using commercial bovine enzyme and fluorometric detection, comparison of fluorogenic reagents, enzyme activity in human urine samples
additional information
-
activity measured as turbidicity reducing units
additional information
-
activity measured as turbidicity reducing units
additional information
-
activity measured as turbidicity reducing units
additional information
-
activity measured in national formulary units
additional information
-
activity measured as turbidicity reducing units
additional information
-
method for Reissig colorimetric assay, kinetic analysis
additional information
-
-
additional information
-
development of a highly sensitive fluorometric assay method using a chromogenic reaction with the N-acetylglucosamine residues at the reducing ends produced by the enzymic cleavage, mechanism, overview
additional information
-
activity in serum samples, development of a highly sensitive fluorometric assay method using a chromogenic reaction with the N-acetylglucosamine residues at the reducing ends produced by the enzymic cleavage, mechanism, overview
additional information
-
-
additional information
-
enzyme activity in different serum samples
additional information
-
isozyme NNH2
additional information
-
purified isozymes NNH1 and NNH2
additional information
-
commercial preparation
additional information
-
enzyme shows low enzymatic activity. Hyaluronan is the preferred substrate
additional information
-
enzyme shows pronounced enzymatic activity
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
3 - 3.3
E7FI87
-
3.3 - 4
-
with 0.15 M NaCl
3.5 - 4
-
-
3.8
-
assay at
3.8
Q08169
-
3.8
synthetic construct
EU152302
-
3.8
-
assay at
4
-
additional slight activity peak observed at pH 7.0
4.2
O43820, Q12794, Q12891
assay at; assay at; assay at
4.2
-
optimal pH
4.5 - 5
-
-
4.5
Palamneus gravimanus
-
-
4.5
-
wild type enzyme
5
-
assay at
5
-
assay at
5
-
assay at
5
-
assay at
5.4
-
in 50 mM sodium-acetate buffer, optimum pH depends on buffer used
5.4
-
broad optimum below, pH-activity curve depends on hyaluronate-enzyme and enzyme-inhibitor interactions
5.5
-
-
6
-
assay at
6
-
assay at
6.3
-
assay
6.5
-
assay at
7
-
assay at
7
-
assay at
7
-
assay at
7
-
assay at
9.6
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
2.5 - 9
-
the optimum activity at pH 3.8 decreases by half at pH 2.5 and 6.0 and is virtually abolished at pH 9.0
2.8 - 4.1
Q8VEI3
-
3 - 8
Q08169
; native and the recombinant enzyme are active at extreme conditions
3 - 8
synthetic construct
EU152302
native and the recombinant enzyme are active at extreme conditions
3 - 9
-
-
3.8 - 11
-
the enzyme is active over a wide pH range
4 - 7
B3EWP2
about 40% activity at pH 4.0, more than 90% activity at pH 5.0-6.0, about 50% activity at pH 6.5, about 10% activity at pH 7.0
4 - 8
-
55000 Da form
4.3
E7FI87
no activity above
5 - 8
E5RWZ0
-
6 - 8
-
70000 and 80000 Da enzymes
additional information
Q8UVT7
narrow activity range in the slightly acidic and neutral pH, inactive below pH 5.4
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
22
-
assay at room temperature
37
-
assay at
37
-
assay
37
-
assay at
37
-
assay at
37
-
assay at
37
-
assay at
37
-
assay at
37
-
assay at
37
Palamneus gravimanus
-
-
37
O43820, Q12794, Q12891
assay at; assay at; assay at
37
-
assay at
37
-
assay at
37
P86100
assay at
37
-
assay at
37
-
assay at
37
-
assay at
37
-
assay at
40
-
maximal activity
45
-
sharp decrease of activity above
50
P86100
optimal activity
62
Q08169
-
62
synthetic construct
EU152302
-
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
4 - 90
Q08169
; 34% activity at temperatures as low as 4C still exhibits hydrolase activity at 90C to an extent of 19% in comparison to the optimum
4 - 90
synthetic construct
EU152302
34% activity at temperatures as low as 4C still exhibits hydrolase activity at 90C to an extent of 19% in comparison to the optimum
20 - 55
-
more than 50% activity between 20 and 55C. Activity is abolished at 60C
25 - 50
B3EWP2
more than 50% activity between 25 and 50C
37 - 46
E7FI87
more than 80% of maximum activity within
pI VALUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
5.1
-
isoelectric focusing, 6 isoforms
9.2
-
isoelectric focusing
9.7
-
isoelectric focusing, isozyme NNH2
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
O60502
primary pilocytic
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
high expression
Manually annotated by BRENDA team
O43820, Q12794
tissue and cells
Manually annotated by BRENDA team
O43820, Q12794
G1 tumour tissue
Manually annotated by BRENDA team
O43820, Q12794
G2 and G3 tumour tissues, and invasive tumour cells
Manually annotated by BRENDA team
-
contains only HYAL2 but not HYAL1
Manually annotated by BRENDA team
O35632
contains only HYAL2 but not HYAL1
Manually annotated by BRENDA team
-
Hyal-like activity is present in the apical and basolateral secretions from HBE cells where Hyals 1, 2, and 3 are expressed
Manually annotated by BRENDA team
-
increased expression and activity is observed in tracheal sections and in bronchoalveolar lavage (BAL) obtained from subjects with asthma when compared with normal lung donors and healthy volunteers
Manually annotated by BRENDA team
-
derived from carcinoma cell lines
Manually annotated by BRENDA team
-
cell line derived from newborn H-2kb tsA58 transgenic mice
Manually annotated by BRENDA team
-
cells form tubular structures after stimulation by angiogenic factors, e.g. the enzyme and the basic fibroblast growth factor bFGF, treatment leads to cell survival and prevents from apoptosis, respectively
Manually annotated by BRENDA team
-
Hyal3 is expressed in epididymal tissue/fluid, from where it is acquired by caudal mouse sperm in vitro
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
high expression
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
-
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
high expression
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
low expression
Manually annotated by BRENDA team
O43820, Q12794
-
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
-
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
high expression
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
low expression
Manually annotated by BRENDA team
Q76HM9
isoform HYAL 4 has little expression in the renal papilla, isoforms HYAL 1 is highly expressed in the renal papilla, isoforms HYAL 2 is highly expressed in the renal papilla, isoforms HYAL 3 is highly expressed in the renal papilla
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
high expression
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
high expression
Manually annotated by BRENDA team
-
high expression
Manually annotated by BRENDA team
-
contains only HYAL2 but not HYAL1
Manually annotated by BRENDA team
O35632
contains only HYAL2 but not HYAL1
Manually annotated by BRENDA team
O43820, Q12794
-
Manually annotated by BRENDA team
-
soluble and acrosome-bound isoforms
Manually annotated by BRENDA team
-
soluble and acrosome-bound isoforms
Manually annotated by BRENDA team
-
from mice grafted with human-tumour-derived, enzyme secreting H460M or SA87 cells, and mice grafted with enzyme non-secreting CB 193 cells
Manually annotated by BRENDA team
-
Hyal3 is expressed in epididymal tissue/fluid, from where it is acquired by caudal mouse sperm in vitro
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
-
Manually annotated by BRENDA team
-
high expression
Manually annotated by BRENDA team
Ovis aries aries
-
-
Manually annotated by BRENDA team
-
commercial preparation
Manually annotated by BRENDA team
-
high expression in adult male testis
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
high expression in adult male testis, low expression in young male testis
Manually annotated by BRENDA team
Q6RHW2, Q6RHW3, Q6RHW4
low expression
Manually annotated by BRENDA team
O60502
glioblastoma cell line
Manually annotated by BRENDA team
Palamneus gravimanus
-
-
Manually annotated by BRENDA team
-
contains a high molecular weight isoform
Manually annotated by BRENDA team
Sus scrofa, Bos taurus, Ovis aries aries
-
-
Manually annotated by BRENDA team
additional information
O43820, Q12794
tissue distribution
Manually annotated by BRENDA team
additional information
O60502
both splice variants of gene mgea5 are ubiquitously expressed in various tissues
Manually annotated by BRENDA team
additional information
-
during virus maturation in the host cell, the enzyme is located at the cell surface by a GPI-anchor
Manually annotated by BRENDA team
additional information
Q6RHW2, Q6RHW3, Q6RHW4
level and pattern of Hyal1 expression in different tissues
Manually annotated by BRENDA team
additional information
Q6RHW2, Q6RHW3, Q6RHW4
level and pattern of Hyal2 expression in different tissues
Manually annotated by BRENDA team
additional information
Q6RHW2, Q6RHW3, Q6RHW4
level and pattern of Hyal3 expression in different tissues
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
-
glycosylphosphatidyl-inositol-linked isoform
-
Manually annotated by BRENDA team
-
spermatid, HPH-20
-
Manually annotated by BRENDA team
-
mouse isoforms are differentially distributed in the soluble, membrane, and acrosome-related fraction, where they are most abundant
-
Manually annotated by BRENDA team
-
Hyal2 is partly expressed at the cell surface
Manually annotated by BRENDA team
O60502
130 kDa enzyme form
Manually annotated by BRENDA team
O60502
130 kDa enzyme form
Manually annotated by BRENDA team
-
secreted to the venom
-
Manually annotated by BRENDA team
-
secreted to the venom
-
Manually annotated by BRENDA team
-
released from sperm
-
Manually annotated by BRENDA team
-
from venom sacs
-
Manually annotated by BRENDA team
-
secreted from cell culture
-
Manually annotated by BRENDA team
-
secreted from cell culture
-
Manually annotated by BRENDA team
Palamneus gravimanus
-
venom
-
Manually annotated by BRENDA team
Q801Z8
venom gland enzyme
Manually annotated by BRENDA team
O60502
130 kDa enzyme form
Manually annotated by BRENDA team
-
inner acrosomal membrane
Manually annotated by BRENDA team
-
Hyal2 is strongly associated with cell membrane fractions from which it can be extracted using a Triton X-114 treatment, but not an osmotic shock or an alkaline carbonate solution. Treatment of membrane preparations with phosphatidylinositol-specific phospholipase C releases immunoreactive Hyal2 into the aqueous phase. The protein is attached to the membrane through a functional GPI anchor. Hyal2 transfected in COS-7 cells is associated with detergent-resistant, cholesterol-rich membranes known as lipid rafts
Manually annotated by BRENDA team
O60502
75 kDa enzyme form
Manually annotated by BRENDA team
O43820, Q12794, Q12891
-
Manually annotated by BRENDA team
O43820, Q12794, Q12891
also expressed at the apical pole associated with the plasma membrane in bronchial epithelial cells
Manually annotated by BRENDA team
-
mouse isoforms are differentially distributed in the soluble, membrane, and acrosome-related fraction, where they are most abundant. Protein resides in the membrane over the sperm head and midpiece, protein resides in the membrane over the sperm head and midpiece
Manually annotated by BRENDA team
-
mouse isoforms are differentially distributed in the soluble, membrane, and acrosome-related fraction, where they are most abundant
-
Manually annotated by BRENDA team
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
30000
E7FI87
PAGE
715032
35000
-
SDS-PAGE under non-reducing conditions, major band at 35000 Da
700874
40000
Eusimulium latipes, Odagmia ornata
-
SDS-PAGE under non-reducing conditions
700874
42260
-
MALDI-TOF mass spectrometry
682931
45000
-
SDS-PAGE
678378
47370
-
calculated from sequence of cDNA
678292
48300
-
recombinant enzyme from Escherichia coli, SDS-PAGE
680043
48700
P86100
using MALDI-TOF
697469
50000
-
SDS-PAGE under non-reducing conditions
700874
50870
-
MALDI-TOF mass spectrometry
678292
52000
Palamneus gravimanus
-
gel filtration
666984
52000
-
SDS-PAGE under non-reducing conditions, three enzyme bands are detected the most prominent one at 52000 Da
700874
52000
-
SPAM1
702526
52000
-
SDS-PAGE
704586
54000
-
isozyme NNH2, gel filtration
664151
54000
-
recombinant enzyme from Drosophila melanogaster Schneider-2 cells, SDS-PAGE
680043
55000
-
SDS-PAGE
171403
55000
-
SDS-PAGE
678378
55000
-
SDS-PAGE, the 55000 Da enzyme form is active both at the acidic (pH 3.7) and the neutral pH (pH 7.4) and is able to bind to heparin
682896
55000
-
HYAL5
702526
55000
-
gel filtration
730300
59000
-
SDS-PAGE
171396
59000
E5RWZ0
gel filtration
716966
62000
-
SDS-PAGE, gel filration
171402
65000
-
SDS-PAGE, the 65000 Da enzyme form found in seminal vesicle fluids is active only at acidic pH and does not interact with heparin
682896
68000
-
gel filtration, acrosome-bound isoform
171397
70000
Ovis aries aries
-
-
171408
70000
-
SDS-PAGE, the 70000 Da enzyme form is active only at neutral pH
682896
70000
-
SDS-PAGE under non-reducing conditions, minor band at 70000 Da
700874
70000
-
SDS-PAGE under non-reducing conditions
700874
70410
-
mass spectrometry, isozyme NNH1
664241
73000
-
primary band at about 73 kDa, gel filtration
701634
74000
-
isozyme NNH1, gel filtration
664152
79000
-
gel filtration
701325
80000
-
SDS-PAGE, the 80000 Da enzyme form is active only at neutral pH
682896
80000
-
SDS-PAGE, presumably glycosylated (53000 Da, expected molecular mass)
693055
82000
-
SDS-PAGE
171404
320000
-
gel filtration, native PAGE
171394
additional information
Q8VEI3
presence of multiple forms of Hyal3 ranging from about 45000 to 56000 Da in expression lysates
680047
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
?
-
x * 66000, SDS-PAGE
?
-
x * 52000, SDS-PAGE
?
-
x * 50000, SDS-PAGE
?
-
x * 64000, SDS-PAGE
?
O60502
x * 130000, enzyme form 1, SDS-PAGE, x * 75000, enzyme form 2, SDS-PAGE
?
-
x * 59290, mass spectrometry, x * 61000, SDS-PAGE
?
P86100
x * 48696, using MALDI-TOF
?
-
x * 43000 and x * 47000, SDS-PAGE, x * 47000 and x * 55000, SDS-PAGE
?
R4J7Z9
x * 45000, His-tag fusion protein, SDS-PAGE
dimer
-
2 * 35000, SDS-PAGE under non-reducing conditions
monomer
-
1 * 62000, SDS-PAGE
monomer
B3EWP2
1 * 64500, SDS-PAGE
monomer
-
1 * 55000, SDS-PAGE
monomer
-
1 * 55000, SDS-PAGE
monomer
Palamneus gravimanus
-
1 * 52000, SDS-PAGE
monomer
-
1 * 82000, SDS-PAGE
monomer
-
1 * 52000, isozyme NNH2, SDS-PAGE
monomer
-
1 * 69000, isozyme NNH1, SDS-PAGE
monomer
-
1 * 79000 Da, gel filtration and SDS-PAGE
monomer
E7FI87
1 * 30000, SDS-PAGE, 1 * 31700, calculated
additional information
-
2 isoforms of approximately 33 kDa and 14 kDa
additional information
-
2 isoforms of approximately 55 kDa and 75 kDa, a high molecular weight isoform in venom
additional information
-
2 isoforms of approximately 61 kDa each
additional information
-
three-dimensional structure analysis
additional information
-
three-dimensional structure analysis and modeling of isozymes, structure-reaction mechanism relationship, overview
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
glycoprotein
B3EWP2
-
glycoprotein
-
-
glycoprotein
-
-
glycoprotein
-
mannosylation at Trp130 negatively regulate enzyme secretion and attenuates enzymatic activity
proteolytic modification
O60502
posttranslational modification of a larger protein of 130 kDa to a 75 kDa form
glycoprotein
-
N-glycosylation is absolutely necessary for activity, deglycosylation leads to complete loss of activity, enzyme binds to lectins Con A, LEL, STL, PHA-e, Jacalin, and PSA, mannose is the major sugar within and at the terminal sequence of the glycans
glycoprotein
Q8VEI3
-
glycoprotein
-
-
glycoprotein
Q801Z8
the enzyme contains three potential N-glycosylation sites
proteolytic modification
Q801Z8
the precursor enzyme contains a signal sequence for targeting into endoplasmic reticulum
glycoprotein
E5RWZ0
sequence is predicted to have potential N-glycosylation sites at the positions 78, 169 and 364
proteolytic modification
E5RWZ0
sequence contains a N-terminal signal pepitde of 28 amino acids
no modification
Q8UVT7
-
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
8-10 mg/ml purified recombinant enzyme, with or wihtout hexameric hyaluronic acid, in 5 mM sodium acetate, pH 5.4, hanging drop vapour diffusion method, 20C, for triclinic crystals, equal volume of protein solution with reservoir solution containing 30% PEG 8000, 0.1 M sodium cacodylate, pH 6.5, 0.2 M ammonium sulfate, equilibration against the reservoir solution, 6-8 months, for monoclinic crystal growth within several days, 10% PEG 6000, 1.0 M NaCl, 20 mM acetic acid, pH 4.2 is used for mixing and equilibration, X-ray diffraction structure determination and analysis at 1.6-2.7 A resolution
Q08169
three-dimensional structure analysis
-
hanging drop vapour diffusion method with mother liquor containing 1.5 M NaCl, 10% (v/v) ethanol, and 1/10 volume of 30% (w/v) galactose, at pH 4.6
-
pH STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
3 - 8
Q08169
native and recombinant enzyme exhibit activity
682687
3 - 8
synthetic construct
EU152302
native and recombinant enzyme exhibit activity
682687
3
-
unstable below
171406
3.7
-
HAase activity is only detectable in acidic conditions of a pH 3.7 buffer
678378
4 - 6
-
stable within
171404
4.9
-
no activity above
171395
5
Q8VEI3
no detectable activity at pH 5.0 or above
680047
5.1 - 5.9
-
human serum hyaluronidase 1 is inactive above pH 5.1, while human serum hyaluronidase 1 variant HYAL1DELTAL exhibits activity up to pH 5.9
704505
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
4 - 90
Q08169
34% activity at temperatures as low as 4C still exhibits hydrolase activity at 90C to an extent of 19% in comparison to the optimum
682687
4 - 90
synthetic construct
EU152302
34% activity at temperatures as low as 4C still exhibits hydrolase activity at 90C to an extent of 19% in comparison to the optimum
682687
30 - 40
Palamneus gravimanus
-
stable, purified enzyme
666984
30
-
enzyme is stable for at least 30 min when incubated at 20C and 30C
701325
40
-
enzyme loses 70% of the activity at 40C
701325
50
-
in the presence of gelatin twice as active as at 37C
171410
50
E7FI87
1 h, pH 3.0, more than 95% of initial activity
715032
60
-
inactivation
650509
65
-
complete inactivation above
171410
90
Q08169
19% activity at 90C
682687
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
adding bovine serum albumin (1.0 mg/ml) to the enzyme sample prior to freezing results in complete retention of enzyme activity
-
at room temperature activity rapidly lost, addition of a peptide derived from gelatin increases stability
-
enzyme activity lost by freezing, addition of bovine serum albumin or 1% dimethylsulfoxide, v/v, prevents inactivation
-
NaCl stabilizes at 0.15 M
Palamneus gravimanus
-
extremely labile, addition of 1% bovine serum albumin prevents inactivation for more than 1 month at -70C
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
22C, 100 mM sodium acetate buffer (pH 3.8) containing 150 mM NaCl, 4 weeks, 58% activity retained
-
4C, 100 mM sodium acetate buffer (pH 3.8) containing 150 mM NaCl, 4 weeks, 92% activity retained
-
7C, purification buffer, 60 days, remains stable
B3EWP2
-20C, purified enzyme, 0.15 M NaCl, stable for 2 months
Palamneus gravimanus
-
4C, purified enzyme, 0.15 M NaCl, stable for 1 month
Palamneus gravimanus
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
by ion exchange chromatography at pH 5.0; HiTrap HP SP column chromatography
Q08169
recombinant His-tagged enzyme
Q08169
SP Sepharose column chromatography and Sephacryl S-100 gel filtration
-
commercial product
-
further purification of the commercial preparation
-
partial
-
CM-cellulose-52 column chromatography, phenyl-Sepharose column chromatography, and Sephacryl S-100 gel filtration
B3EWP2
to homogeneity, 2step chromatography
-
Sephadex G-100 column chromatography and CM-Sephadex C-25 column chromatography
-
ammonium sulfate precipitation and Ni-ion metal affinity chromatography
-
Chelating Sepharose Fast Flow column chromatography and Sephacryl S200 gel filtration
-
HiTrap Q column chromatography and Superdex 200 HR 10/30 gel filtration
-
Hyal2 is strongly associated with cell membrane fractions from which it can be extracted using a Triton X-114 treatment, but not an osmotic shock or an alkaline carbonate solution. Treatment of membrane preparations with phosphatidylinositol-specific phospholipase C releases immunoreactive Hyal2 into the aqueous phase. The protein is attached to the membrane through a functional GPI anchor. Hyal2 transfected in COS-7 cells is associated with detergent-resistant, cholesterol-rich membranes known as lipid rafts
-
partial
-
recombinant protein; recombinant protein; recombinant protein; recombinant protein
O43820, Q2M3T9
to homogeneity, chromatography steps
-
recombinant His6-tagged viral enzyme from insect cells by metal affinity chromatography, ultrafiltration, and gel filtration
-
from sperm surface by treatment with phosphatidylinositol-specific phospholipase C
-
using successive chromatography: gel filtration, anion exchange chromatography, cation exchange chromatography, reversed-phase HPLC
P86100
partial
-
isozymes NNH1 and NNH2 33fold and 26fold, respectively, from venom by gel filtration and ion exchange chromatography
-
native isozyme NNH1 33fold to homogeneity from venom by successive gel filtration and ion exchange chromatography
-
native isozyme NNH2 26fold to homogeneity from venom by successive gel filtration and ion exchange chromatography
-
partial
Ovis aries aries
-
25.6fold to homogeneity from venom by gel filtration and ion exchange chromatography
Palamneus gravimanus
-
native enzyme
E7FI87
purified by gel filtration on Sephacryl S-100 and ion-exchange chromatography on SP-Sepharose. Procedure provides 376.4fold purification with a 2.94% yield
-
to homogeneity, chromatography, isoelectric focusing
-
heparin-Sepharose column chromatography
-
native enzyme from lyophilized venom by affinity chromatography
Q801Z8
to homogeneity, 2step chromatography
-
partial
E5RWZ0
by ion exchange chromatography at pH 5.0
synthetic construct
EU152302
Sephadex G-50 gel filtration; Sephadex G-50 gel filtration
P85841, W0HFN9
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
DNA and amino acid sequence analysis, expression as active C-terminally His-tagged enzyme in insect cells via baculovirus infection
Q08169
expressed in Pichia pastoris strain GS115; expression in Pichia pastoris GS115, expression vector pPIC9, together with human serum albumin, expression in Escherichia coli BL21 DE3, vector pMW172, fusion protein
Q08169
cloning of core nucleotide sequence in two fused fragments, PH-20 gene DNA and amino acid sequence determination and analysis, sequence comparisons and phylogenetic analysis
Q7YS45
expressed in Pichia pastoris
-
;
Q12794, Q12891
DNA and amino acid sequence determination and analysis, in vitro translation
O43820, Q12794
expressed in 22Rv1 human prostate adenomacarcinoma cells and in HEK-293 human embryonic kidney cells as a N-terminal FLAG fusion protein. Abundant soluble FLAG-tagged Hyal1 is secreted to the conditioned cell culture media of transfectants; FLAG-tag
-
expressed in COS-7 cells
-
expressed in Drosophila melanogaster Schneider 2 cells
-
expressed in Escherichia coli and in Xenopus laevis oocytes
-
expressed in Escherichia coli BL21(DE3)RIL cells and Drosophila melanogaster Schneider-2 cells
-
expressed in S-2 cells
-
expression in human bronchial epithelial cell (HBE); expression in human bronchial epithelial cell (HBE); expression in human bronchial epithelial cell (HBE)
O43820, Q12794, Q12891
gene mgea5, DNA sequence determination and analysis, genomic organization on chromosome 10, 2 splice variants, one missing a putative acetyltransferase domain of the enzyme
O60502
isozymes Hyal1-Hyal4, sequence comparison, the genes encoding isozymes Hyal1-Hyal3 are tightly clustered on chromosome 3q21.3, Hyal4 and HPH-20 are clustered on 7q31.3, expression profiles
-
transfection of COS-7 cell
-
transient expression in Nicotiana benthamiana; transient expression in Nicotiana benthamiana; transient expression in Nicotiana benthamiana; transient expression in Nicotiana benthamiana
O43820, Q2M3T9
expression of His6-tagged viral enzyme via baculovirus transfection in Spodoptera frugiperda Sf9 insect cells, the His-tag replaces the GPI anchor of the enzyme to make it soluble
-
expressed in Escherichia coli BL21(DE3)pLysS cells
R4J7Z9
expressed in baby hamster kidney cells
Q8VEI3
expressed in COS-7 cells
-
isozymes are clustered on chromosome 9F1-F2 and 6A2, expression profiles
-
expression in Escherichia coli
E7FI87
genes HYAL1, HYAL2, and HYAL3 are clustered on chromosome SSC13q21, DNA and amino acid sequence determination and analysis; genes HYAL1, HYAL2, and HYAL3 clustered on chromosome SSC13q21, DNA and amino acid sequence determination and analysis; genes HYAL1, HYAL2, and HYAL3 clustered on chromosome SSC13q21, DNA and amino acid sequence determination and analysis
Q6RHW2, Q6RHW3, Q6RHW4
precursor from venom gland, DNA and amino acid sequence determination and analysis, phylogenetic analysis and sequence comparisons, functional expression of His-tagged enzyme in insect cells, but not in Escherichia coli, and secretion of the recombinant enzyme, overview
Q801Z8
using the information of preferred Pichia pastoris codons as provided by Genscript, Inc., the native sequence is de novo synthesized to create a fully codon-optimized cDNA (Hya delta c) and the synthetic gene is expressed in Pichia
synthetic construct
EU152302
DNA and amino acid sequence determination and analysis, expressed by injection of mRNA in frog oocytes on the outer surface of the cell membrane
Q8UVT7
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
basic fibroblast growth factor decreases hyaluronidase-2 expression in HT-1080 cells
-
the median of isoform HYAL1 mRNA level is 69% lower in grade 3 serous ovarian cancers compared to normal ovaries
-
estrogen receptor(-) breast cancer cells secrete significantly more hyaluronidase than estrogen receptor(+) breast cancer cells
-
hyaluronidase activity is elevated in dehydrated rats
-
hyaluronidase-1 activity is increased in the lungs of monocrotaline-challenged rats
-
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
D129N
-
catalytic mutant, catalysis impaired, catalytic mutant, Km higher compared to wild-type, Vmax lower than wild-type
D146N
-
site-directed mutagenesis of HPH-20, the mutant shows highly reduced activity
DELTA351-end
-
putative structural mutant with a deleted EGF-like domain, significant decreased enzymatic activity
DELTA356-end
-
putative structural mutant with a deleted EGF-like domain, significant decreased enzymatic activity
E131Q
-
catalytic mutant, activity eliminated, catalytic mutant, no measurable activity
E148Q
-
site-directed mutagenesis of HPH-20, inactive mutant
N216A
-
putative structural mutant, reduced activity, putative structural mutant, Km higher compared to wild-type, Vmax unaltered compared to wild-type, ca. 44% of wild-type activity
N350A
-
putative structural mutant, reduced activity, putative structural mutant, significant decreased enzymatic activity
N350tr
-
putative structural mutant, reduced activity
R265L
-
putative structural mutant, reduced activity, putative structural mutant, significant decreased enzymatic activity
S245A
-
substrate binding mutant, reduced activity, substrate binding mutant, Km higher compared to wild-type, Vmax unaltered compared to wild-type, ca. 41% of wild-type activity
Y202F
-
substrate binding mutant, catalysis impaired, substrate binding mutant, Km higher compared to wild-type, Vmax lower than wild-type
additional information
Q08169
after expression of a fusion protein by linking hyaluronidase and human serum albumin together with the recognition sequence for the protease, factorXa, fragmented protein products are obtained in the culture supernatant, only after replacement of the hinge region with a serine-glycine-rich linker, stable full-length fusion protein could be generated, when changing the codons of the original transcript to triplet sequences preferred by Pichia pastoris, no further increase of protein product can be achieved
additional information
-
the effect of hyaluronidase coinoculation on the outcome of Leishmania major infection in BALB/c mice: Hyaluronidase exacerbates skin lesions caused by Leishmania major, more severe lesions developed in mice where Leishmania major promastigotes are coinjected with hyaluronidase
L356tr
-
putative structural mutant, reduced activity
additional information
-
expression as PH-20-autotransporter fusion protein for cell surface display in Escherichia coli F470, a strain missing the O-polysaccharide of LPS, yields cells with sufficient hyaluronidase activity
Y247F
-
catalytic mutant, activity eliminated, catalytic mutant, no measurable activity
additional information
P86100
the expression of CD44v6 is reduced when MDA-MB-231 cancer cells are treated with BmHYA1 for 48 h
additional information
synthetic construct
EU152302
after expression of a fusion protein by linking hyaluronidase and human serum albumin together with the recognition sequence for the protease, factorXa, fragmented protein products are obtained in the culture supernatant, only after replacement of the hinge region with a serine-glycine-rich linker, stable full-length fusion protein could be generated, when changing the codons of the original transcript to triplet sequences preferred by Pichia pastoris, no further increase of protein product can be achieved
Renatured/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
using 100 mM Tris-HCl pH 10.0, 3 mM reduced glutathione, 0.3 mM oxidized glutathione, 0.4 M L-arginine, 0.2 mg bovine serum albumin
R4J7Z9
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
medicine
Q08169
enzyme is the target for immunotherapy of allergen reaction
medicine
Q08169
this recombinant hyaluronidase can be applied for biochemical or medical purposes
biotechnology
-
a fluorescent substrate (FRET-HA) to quantitatively assess hyaluronidase activity is developed
biotechnology
-
novel products in hyaluronan digested by commercially available bovine testicular hyaluronidase are found which originate from a novel enzyme contaminat in the BTH
medicine
-
increasing absorption of fluids in dermal clysis, increasing diffusion of injected substances
medicine
-
hyaluronidase promotes Leishmania establishment in murine skin
medicine
-
hyaluronidase improves pharmacokinetic profiles of HI-6 dichloride and HI-6 dimethansulfonate. Hyaluronidase is supposed to increase tissue permeability and diminishes discomfort caused by the intramuscular injection
diagnostics
O43820, Q12794
increased concentration of HYAL1-type enzyme correlates with tumour progression and is a marker for grade (G) 2 or 3 bladder cancer
medicine
-
as major hyaluronidases in human cells, HYAL1 and HYAL2 may control intercellular interactions and microenvironment of tumour cells providing excellent targets for cancer treatment
medicine
-
human cancers grown in SCID mice regress dramatically following administration of purified testicular hyaluronidase. Hyaluronidase treatment also prevents lymph node invasion in a murine model for T-cell lymphoma, hyaluronidase correlates with tumor progression which is documented in tumors of the male genito-urinary tract, in prostate and urinary bladder cancers. Aggressiveness of other human cancers also correlates with hyaluronidase, including breast and laryngeal cancer, hyaluronidases are added to anticancer regimens, particularly in Europe. Tumors previously resistant to chemotherapy become sensitive when hyaluronidase is added. The enzyme may decrease intratumoral pressure, permitting drugs to penetrate the malignancy. Studies are available suggesting that hyaluronidase has intrinsic anti-tumor activity
medicine
-
it is assessed whether hyaluronic acid and HYAL-1 can predict progression to muscle invasion and recurrence among patients with non-muscle-invasive bladder carcinoma. In a cohort of 178 bladder carcinoma specimens HA and HYAL-1 expression is evaluated by immunohistochemistry and graded for intensity and area of staining. Association of HA and HYAL-1 staining with bladder carcinoma recurrence and muscle invasion is evaluated by univariate and multivariate models. HYAL-1 is a potential prognostic marker for predicting progression to muscle invasion and recurrence
medicine
-
the codelivery of hyaluronidase enzyme with oncolytic adenoviruses is analysed to determine whether it improves the spread of the virus throughout tumors, thereby leading to a greater overall antitumor efficacy in tumor models: In mice injected with the adenovirus Ad5/35GFP and hyaluronidase (50 U), a significant increase in the number of GFP-expressing cells is observed when compared with animals injected with virus only. When the oncolytic adenoviruses Ad5OV or Ad5/35 OV are codelivered with 50 U of hyaluronidase, a significant delay in tumor progression is observed, which translates into a significant increase in the mean survival time of tumor-bearing mice compared with either of the monotherapy-treated groups. Furthermore, the mice that receive the combination of Ad5/35 OV and hyaluronidase show the best antitumor efficacy
medicine
-
the effect of anticoagulants on plasma HAase activity is evaluated and compared with the serum HAase activity that is devoid of anticoagulants. The plasma HAase activity in the presence of the recommended concentration of EDTA is highly comparable to that of the serum HAase activity. In contrast, citrated or heparinized plasma record a significantly reduced level of activity than that of the serum HAase activity. EDTA-treated plasma samples are a better choice compared with heparin and citrated samples to assess the HAase activity
medicine
-
hyaluronidase 1 is a prognostic indicator for both local recurrence and progression of non-muscle-invasive bladder cancer after transurethral resection
medicine
-
isoforms of hyaluronidase are predictors of a prostate cancer of good prognosis
molecular biology
-
the influence of hyaluronidase digestion modulates CD44 expression in various cancer cell lines
analysis
-
cancer cell lines often secrete hyaluronidase, the enzyme might therefore be a marker for growing tumours
pharmacology
-
isozyme NNH1 is a target for first aid agents from plants in snakebit therapy
medicine
-
intravitreous injection of ovine hyaluronidase to patients with persistent vitreous hemorrhage is efficacious and has a favorable safety profile
medicine
synthetic construct
EU152302
this recombinant hyaluronidase can be applied for biochemical or medical purposes